The purpose of this study is to develop a measurement of walking quality, called Gait Deviation Index (GDI) for people with Multiple Sclerosis (MS).

In rehabilitation in general, in order to track patients' progress and provide next steps, there is a need for easily obtainable, understandable, and objective measures of ability. Currently, there is no measure that clinicians can utilize to determine walking quality. While Gait Deviation Index has been validated and can reliably be used in adults who experienced a Spinal Cord Injury, it has not yet been validated in people with MS. After the MS-specific GDI is developed from this study, therapists and clinicians will be able use it as a reliable progress measure. Which may lead to the delivery of more effective therapy for patients with MS.

Here we plan to measure body position with camera based tracking during your gait cycle.

Inclusion criteria:

• Diagnosis of relapsing form of MS (including relapsing-remitting MS and secondary progressive MS)
• Able to ambulate overground
• Relapse free for at least 1 month
• Age ≥18 and ≤ 75 years
• Participants using dalfampridine will be eligible if taking the same daily dose for at least 2 months prior to screening

Exclusion criteria:

- Orthopedic injuries, fractures, surgeries or other conditions affecting locomotor function or weight bearing

Persons with multiple sclerosis who can ambulate overground

Share overall data set